DE69738753D1 - AUF TGF-beta 1 ANSPRECHENDE KNOCHENMARKZELLEN - Google Patents

AUF TGF-beta 1 ANSPRECHENDE KNOCHENMARKZELLEN

Info

Publication number
DE69738753D1
DE69738753D1 DE69738753T DE69738753T DE69738753D1 DE 69738753 D1 DE69738753 D1 DE 69738753D1 DE 69738753 T DE69738753 T DE 69738753T DE 69738753 T DE69738753 T DE 69738753T DE 69738753 D1 DE69738753 D1 DE 69738753D1
Authority
DE
Germany
Prior art keywords
bone marrow
cells
tgf
attractive
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69738753T
Other languages
German (de)
English (en)
Inventor
Erlinda Maria Gordon
Frederick L Hall
W French Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of DE69738753D1 publication Critical patent/DE69738753D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0663Bone marrow mesenchymal stem cells (BM-MSC)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/15Transforming growth factor beta (TGF-β)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/495Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69738753T 1996-11-12 1997-11-12 AUF TGF-beta 1 ANSPRECHENDE KNOCHENMARKZELLEN Expired - Lifetime DE69738753D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/747,514 US6063593A (en) 1996-11-12 1996-11-12 TGFβ1 responsive bone marrow derived cells to express a recombinant protein
PCT/US1997/020558 WO1998020907A1 (en) 1996-11-12 1997-11-12 TGFβ1-RESPONSIVE CELLS FROM BONE MARROW

Publications (1)

Publication Number Publication Date
DE69738753D1 true DE69738753D1 (de) 2008-07-17

Family

ID=25005386

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69738753T Expired - Lifetime DE69738753D1 (de) 1996-11-12 1997-11-12 AUF TGF-beta 1 ANSPRECHENDE KNOCHENMARKZELLEN

Country Status (12)

Country Link
US (4) US6063593A (enExample)
EP (1) EP0946199B1 (enExample)
JP (2) JP2001503989A (enExample)
AT (1) ATE397461T1 (enExample)
AU (1) AU5253498A (enExample)
CA (1) CA2271734A1 (enExample)
DE (1) DE69738753D1 (enExample)
DK (1) DK0946199T3 (enExample)
ES (1) ES2308790T3 (enExample)
NZ (1) NZ335753A (enExample)
PT (1) PT946199E (enExample)
WO (1) WO1998020907A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
CA2379683A1 (en) 1999-07-20 2001-01-25 University Of Southern California Identification of pluripotent pre-mesenchymal, pre-hematopoietic progenitor cell
JP2003018984A (ja) * 2001-07-06 2003-01-21 Mitsubishi Chemicals Corp 多分化能を有する細胞の製造法
US20030129748A1 (en) * 2001-10-26 2003-07-10 Children's Hospital Of Philadelphia Enginerred bone marrow
JP2005531507A (ja) * 2002-03-02 2005-10-20 ザ ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム ストローマ細胞前駆体による抗癌物質の局所的な産生および/または送達方法
US20090221475A9 (en) * 2002-04-01 2009-09-03 Kazunori Murakami Treatment of lung disorders
US20040052771A1 (en) * 2002-07-12 2004-03-18 Lim Sai Kiang Hemangioblast progenitor cells
WO2004007698A1 (en) * 2002-07-12 2004-01-22 National University Of Singapore Hemangioblast progenitor cells
US20040091503A1 (en) 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
EP2319544A1 (en) 2004-01-16 2011-05-11 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
JP2006249072A (ja) * 2005-02-09 2006-09-21 Osaka Univ タンパク質導入用担体、前記担体を用いたタンパク質導入剤、タンパク質導入方法、およびタンパク質導入細胞ならびにその製造方法
KR20170102040A (ko) 2006-04-14 2017-09-06 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
US8263043B2 (en) 2006-04-14 2012-09-11 Carnegie Mellon University Cellular labeling and quantification for nuclear magnetic resonance techniques
EP2170975B1 (en) 2007-07-10 2018-05-02 Carnegie Mellon University Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques
EP3441462A1 (en) 2008-05-06 2019-02-13 Astellas Institute for Regenerative Medicine Hemangio colony forming cells and non-engrafting hemangio cells
CN104328087A (zh) 2008-05-06 2015-02-04 先进细胞技术公司 用于制备衍生自多能干细胞的去核类红细胞的方法
US8583299B2 (en) * 2009-03-17 2013-11-12 General Electric Company System and method for communicating data in a train having one or more locomotive consists
PT2499165T (pt) 2009-11-13 2016-10-28 Grifols Therapeutics Inc Preparações que contêm o fator de von willebrand (vwf), e métodos, kits e utilizações relacionadas com as mesmas
WO2016054107A1 (en) 2014-09-29 2016-04-07 Counterpoint Biomedica Llc Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polymers
US11406721B2 (en) 2016-02-22 2022-08-09 The Regents Of The University Of California Compositions and methods for imaging cell populations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein

Also Published As

Publication number Publication date
US20020141982A1 (en) 2002-10-03
AU5253498A (en) 1998-06-03
US6844191B2 (en) 2005-01-18
EP0946199B1 (en) 2008-06-04
US6277369B1 (en) 2001-08-21
JP2001503989A (ja) 2001-03-27
CA2271734A1 (en) 1998-05-22
ES2308790T3 (es) 2008-12-01
NZ335753A (en) 2001-02-23
EP0946199A1 (en) 1999-10-06
US6063593A (en) 2000-05-16
DK0946199T3 (da) 2008-08-25
ATE397461T1 (de) 2008-06-15
PT946199E (pt) 2008-09-01
US6410015B1 (en) 2002-06-25
JP4767983B2 (ja) 2011-09-07
EP0946199A4 (en) 2002-11-27
WO1998020907A1 (en) 1998-05-22
JP2008206520A (ja) 2008-09-11

Similar Documents

Publication Publication Date Title
DE69738753D1 (de) AUF TGF-beta 1 ANSPRECHENDE KNOCHENMARKZELLEN
AU8476698A (en) Human mesenchymal stem cells from peripheral blood
ATE213271T1 (de) Verfahren zur herstellung von rekombinanten proteinen in e. coli mittels hochzelldichte- fermentation
AU7297298A (en) Apparatus and methods for anchoring autologous or artificial tendon grafts in bone
DE69733605D1 (de) In vivo gentransfermethoden zur wundheilung
EP0765386A4 (en) METHODS FOR ACTIVATION OF IN VIVO T CELLS BY ANTIGENIC PULSE DENDRITIC CELLS
ATE110108T1 (de) Genetische modifizierung von endothelialen zellen.
TW428026B (en) Bifunctional protein, preparation and use
DE69835354D1 (de) Transplantate für myokardiale narben, sowie methode und zelluläre präparationen dafür
ATE474052T1 (de) Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
GB9925964D0 (en) Hair transplantation
WO2001068828A3 (en) Compositions and methods for regulated protein expression in gut
WO1997026322A3 (en) Methods and compositions for inhibiting hexokinase
BR9708049A (pt) Processo para matar células alvo indesejadas em uma população de células imunotoxinas para matar células uso das mesmas e kit para realizar o processo
DE69940753D1 (de) Verfahren zur Einführung von heterologischen Zellen in Fische
CA2445785A1 (en) Artificial kidney having function of metabolizing protein and method of constructing the same
HU9802577D0 (en) In vivo dyeing material, process for producing thereof and use for identifying of living tissues
GR3031229T3 (en) Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease
DE69734464D1 (de) Verfahren zur expression und herstellung von rekombinantem, menschlichem beta-cis-interferon
IL128569A0 (en) Fibroblast growth factor homologous factor S(FHFs) and methods of use
WO2002050111A3 (en) Isolated laminin 10
AU4037299A (en) Genetically-modified fibroblasts and the use thereof
DE69737597D1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
EP2295578A3 (en) Cyp1b1 nucleic acids and methods of use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition